Tocilizumab was chosen due to its efficacy in modulating the hyperinflammatory response characteristic of HLH. This is because blockade of the downstream signal transduction of IL-6 can prevent the occurrence of cytokine storm and, subsequently, clinical manifestations of HLH [21]. This evidence concerns the gene IL6 and hemophagocytic syndrome.